Hormonal status of patients with CRF on program hemodialysis
Abstract
We studied hormonal status of 10 male patients from 41 to 69 years old with the end stage chronic kidney disease for 3–18 years and were treated with a program hemodialysis for 0,5–11 years before and just after a hemodialysis session. Using of immunoenzyme analysis the plasma concentration of the following hormones was assesed: aldosterone, cortisol, dehydroepiandrosterone-sulphate, insulin, C-peptide, parathormone, calcitonine, thyroxine, testosterone and estradiol. As the control 21 practically healthy volunteersof the same gender and age are used. In the interdialysis period a significant increase in plasma concentration of aldosterone, cortisol, parathormone, calcitonine, and C-peptide compared to control values has been found. After the 4-hour session of hemodialysis the concentration of aldosterone, insulin, C-peptide, parathormone, and testosterone significantly decreased, while the level of thyroxine increased. A correlation between concentrations of some hormones was revealed. It was essentially different in before dialysis compared to control; after the dialysis the quantity and an orientation of correlative ties came close to control. A dependence of concentration of separate hormones with on age, the duration of illness and hemodialysis, the presence of an arterial hypertension, anaemia, heart insufficiency, and renal osteodystrophy was established.
About the Authors
I. V. Berezina
Novosibirsk regional hospital
Russian Federation
Russian Federation
E. A. Movchan
Novosibirsk state medical university
Russian Federation
Russian Federation
G. A. Koroschenko
Novosibirsk state pedagogic university
Russian Federation
Russian Federation
O. S. Kogteva
Novosibirsk state pedagogic university
Russian Federation
Russian Federation
A. G. Taranov
Novosibirsk state pedagogic university
Russian Federation
Russian Federation
V. I. Fedorov
Research institute of laser physics, Siberian branch RAS
Russian Federation
Russian Federation
R. I. Aizman
Novosibirsk state pedagogic university
Russian Federation
Russian Federation
References
1. Бехтерева Н.П. Нейрофизиологические аспекты психической деятельности человека. Л.: Медицина, 1971. 118 с.
2. Бикбов В.Т., Томилина Н.А. Состояние заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2007 гг // Нефрология и диализ. 2009. Т. 11. № 3. С. 144–233.
3. Карабаева А.Ж., Есаян А.М., Каюков И.Г. Концентрация альдостерона, состояние гемостаза и эндотелиальной функции у больных на программном гемодиализе и влияние на них терапии спиролактоном // Нефрология. 2008. Т. 12. № 2. С. 56–60.
4. Стецюк Е.А. Основы гемодиализа. М.: ГЭОТАР-Мед, 2001. 320 с.
5. Суботялов М.А. Морфофункциональные и психофизиологические особенности подростков и юношей различных конституциональных типов. Автореф. дисс. …. канд. биол. наук. Томск: ТГУ, 2002. 22 с.
6. Чупрасов В.Б. Программный гемодиализ. СПб.: Фолиант, 2001. 256 с.
7. Augustin R, Hackeng WH. Parathyroid function in patients on chronic intermittent hemodialysis // Klin Wochenschr. 1977. Vol. 155 (16). P. 811–860.
8. Augustyn M., Gosek K. Effect of hemodialysis on the pituitary adrenocortical axis in patients with diabetic nephropathy // Pol Arch Med Wewn. 1996. Vol. 5 (5). P. 433–442.
9. Bomback AS, Kshirsagar AV, Ferris ME, Klemmer PJ. Disordered aldosterone-volume relationship in end-stage kidney disease // J Renin Angiotensin Aldosterone Syst. 2009. Vol. 10 (4). P. 230–236.
10. Deck K.A., Siemon G., Sieberth H.G., von Bayer H. Cortisol loss and plasma 11-hydroxy-corticosteroid profile during hemodialysis // Verh Dtsch Ges Inn Med. 1968. Vol. 74. P. 1195–1198.
11. Drabczyk R., Grzeszczak W., Trelewicz P. Influence of long-term hemodialysis treatment on total and free thyroxine serum concentration in patients with chronic renal failure // Pol Arch Med Wewn. 1992. Vol. 88 (6). P. 359–367.
12. Drabczyk R., Grzeszczak W., Trelewicz P. Influence of long term hemodialysis treatment on TSH secretion in patients with chronic renal failure // Pol Arch Med Wewn. 1992. Vol. 88 (6). P. 381–391.
13. Gross E., Rothstein M., Dombek S., Juknis H.I. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients // Am J Kidney Dis. 2005. Vol. 46 (1). P. 94–101.
14. Grzegorzewska A.E. Metabolic syndrome in dialyzed patients. Diagnosis and insulin resistance // Pol Merkur Lekarski. 2010. Vol. 28 (164). P. 162–165.
15. Jalali G.R., Roozbeh J., Mohammadzadeh A. et al. Impact of oral zinc therapy on the level of sex hormones in male patients on hemodialysis // Ren Fail. 2010. Vol. 32 (4). P. 417–419.
16. Kaneda H, Mimura N. Effect of dialysis treatment on glucose metabolism in uremic patients // Tohoku J Exp Med. 1977. Vol. 122 (1). P. 35–42.
17. Kayima J.K., Otieno L.S., Gitau W., Mwai S. Thyroid hormone profiles in patients with chronic renal failure on conservative management and regular haemodialysis // East Afr Med J. 1992. Vol. 69 (6). P. 333–336.
18. Kokot F., Kuska J., Pietrek J. The behavior of the parathyroid hormone secretion in hemodialyzed patients with chronic kidney failure // Z Gesamte Inn Med. 1975. Vol. 30 (13). P. 443–446.
19. Letizia C., Mazzaferro S., De Ciocchis A. Effects of haemodialysis session on plasma beta-endorphin, ACTH and cortisol in patients with end-stage renal disease // Scand J Urol Nephrol. 1996. Vol. 30 (5). P. 399–402.
20. Levitt H., Smith K.G., Rosner M.H. et al. Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis // Hemodial Int. 2009. Vol. 13 (4). P. 518–525.
21. Louis F., Zwahlen A., Favre H., Vallotton M. The regulation of plasma aldosterone in hemodialysis patients // Schweiz Med Wochenschr. 1980. Vol. 110 (49). P. 1882–1884.
22. Moczulski D., Zukowska-Szczechowska E., Grzeszсzak W. et al. Effect of hemodialysis on the pituitary adrenocortical axis in patients with diabetic nephropathy // Pol Arch Med Wewn. 1996. Vol. 95 (5). P. 433–442.
23. N'Gankam V., Uehlinger D., Dick B. et al. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis // Kidney Int. 2002. Vol. 61 (5). P. 1859–1866.
24. Palmer S.C., McGregor D.O., Craig J.C. et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis // Cochrane Database Syst Rev. 2009. Vol. 7 (4). CD 00563.
25. Rodrґiguez R., Burgos Revilla F.J., Gґomez Dosantos V. et al. Endocrine changes and sexual dysfunction in kidney transplantation and hemodialysis: comparative study // Actas Urol Esp. 1996. Vol. 20 (8). P. 697–701.
26. Sherwin R.S., Bastl C., Finkelstein F.O. et al. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagons // J Clin Invest. 1976. Vol. 57 (3). P. 722–731.
27. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations // Cleve Clin J Med. 2009. Vol. 76 (11). P. 649–655.
28. Starzyk J., Kowalski D. Effect of hemodialysis on levels of parathormone in blood of patients with chronic kidney failure // Wiad Lek. 1993. Vol. 46 (7–8). P. 283–285.
29. Vigna L., Buccianti G., Orsatti A. ey all. The impact of long-term hemodialysis on pituitary-adrenocortical function // Ren Fail. 1995. Vol. 17 (5). P. 629–637.
30. Williams M.E. Management of diabetes in dialysis patients // Curr Diab Rep. 2009. Vol. 9 (6). P. 466–472.
Review
For citations:
Berezina I.V., Movchan E.A., Koroschenko G.A., Kogteva O.S., Taranov A.G., Fedorov V.I., Aizman R.I. Hormonal status of patients with CRF on program hemodialysis. Nephrology and Dialysis. 2011;13(2):076-081. (In Russ.)
Views:
7
Email this article 